Shokouhifar Alireza, Anani Sarab Gholamreza, Yazdanifar Mahboubeh, Fereidouni Mohammad, Nouri Masoumeh, Ebrahimi Marzieh
Department of Molecular Medicine, Genomic Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Cellular & Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Cancer Cell Int. 2021 Jun 7;21(1):298. doi: 10.1186/s12935-021-01983-z.
The natural killer (NK) cells differentiated from umbilical cord blood (UCB) hematopoietic stem cells (HSCs) may be more suitable for cell-based immunotherapy compared to the NK cells from adult donors. This is due to the possibility to choose alloreactive donors and potentially more robust in vivo expansion. However, the cytotoxicity of UCB-HSC-derived NK cells against cancer cells might be suboptimal. To overcome this obstacle, we attempted to generate NK cells with potent antitumor activity by targeting RAS/MAPK, IGF-1R and TGF-β signaling pathways using IL-15, IGF-1 and SIS3 respectively.
The CD34 + cells were isolated from human UCB mononuclear cells through magnetic activation cell sorting (MACS) with purity of (≥ 90%) and were subjected to differentiate into NK cells. After 21 days of induction with SFTG36 (SCF, FLt-3L, TPO, GM-CSF, IL-3 and IL-6), IS721 (IGF-1, SIS3, IL-7 and IL-21) and IL-15/Hsp70 media, NK cells phenotypes were studied and their cytotoxicity against K562 human erythroleukemia cells and SKOV3 ovarian carcinoma cells was analyzed.
The NK cells induced in SFTG36/IS721 medium were selected for activation due to their higher expression of CD56 + 16 + CD3 - (93.23% ± 0.75) and mean fluorescence intensity (MFI) of NKG2D + (168.66 ± 20.00) and also a higher fold expansion potential (11.893 ± 1.712) compared to the other groups. These cells once activated with IL-15, demonstrated a higher cytotoxicity against K562 (≥ 90%; P ≤ 0.001) and SKOV3 tumor cells (≥ 65%; P ≤ 0.001) compared to IL-15/Hsp70-activated NK cells.
The differentiation of ex vivo expanded CD34 + cells through manipulation of RAS/MAPK, IGF-1R and TGF-β signaling pathways is an efficient approach for generating functional NK cells that can be used for cancer immunotherapy.
与来自成年供体的自然杀伤(NK)细胞相比,从脐带血(UCB)造血干细胞(HSC)分化而来的NK细胞可能更适合基于细胞的免疫治疗。这是因为有可能选择同种异体反应性供体,并且在体内可能有更强的扩增能力。然而,UCB-HSC来源的NK细胞对癌细胞的细胞毒性可能并不理想。为了克服这一障碍,我们分别使用白细胞介素-15(IL-15)、胰岛素样生长因子-1(IGF-1)和SIS3靶向RAS/丝裂原活化蛋白激酶(MAPK)、IGF-1受体(IGF-1R)和转化生长因子-β(TGF-β)信号通路,试图生成具有强大抗肿瘤活性的NK细胞。
通过磁激活细胞分选(MACS)从人UCB单个核细胞中分离出CD34+细胞,纯度≥90%,然后使其分化为NK细胞。在用SFTG36(干细胞因子、Flt-3配体、血小板生成素、粒细胞-巨噬细胞集落刺激因子、IL-3和IL-6)、IS721(IGF-1、SIS3、IL-7和IL-21)和IL-15/热休克蛋白70(Hsp70)培养基诱导21天后,研究NK细胞表型,并分析其对K562人红白血病细胞和SKOV3卵巢癌细胞的细胞毒性。
选择在SFTG36/IS721培养基中诱导的NK细胞进行活化,因为它们CD56+16+CD3-的表达较高(93.23%±0.75),自然杀伤细胞激活受体2D(NKG2D)的平均荧光强度(MFI)较高(168.66±20.00),并且与其他组相比具有更高的扩增倍数潜力(11.893±1.712)。与IL-15/Hsp70激活的NK细胞相比,这些细胞一旦用IL-15激活,对K562(≥90%;P≤0.001)和SKOV3肿瘤细胞(≥65%;P≤0.001)表现出更高的细胞毒性。
通过操纵RAS/MAPK、IGF-1R和TGF-β信号通路对体外扩增的CD34+细胞进行分化,是生成可用于癌症免疫治疗的功能性NK细胞的有效方法。